DeepMed Research

Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

SU5416 Combined With Gemcitabine and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-07-19

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005996

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: erlotinib hydrochloride

First Posted Date: 2004-07-12

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00087035

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-07-12

Last Posted Date: 2013-07-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00087061

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Amifostine
Drug: DHAP

First Posted Date: 2004-06-16

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT00003143

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-06-11

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT00085020

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib

First Posted Date: 2004-06-11

Last Posted Date: 2020-08-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00084747

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma

Phase 2

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-06-09

Last Posted Date: 2013-12-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00005084

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-06-09

Last Posted Date: 2013-06-26

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00003410

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Topotecan and Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-06-04

Last Posted Date: 2014-01-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004979

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

Phase 3

Completed

Conditions: Chronic Myeloproliferative Disorders
Myelodysplastic Syndromes
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Cervical Cancer
Precancerous/Nonmalignant Condition
Veno-occlusive Disease
Leukemia

Interventions: Other: placebo
Drug: Fragmin

First Posted Date: 2004-05-26

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00006083

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy